Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to volunteer, sign a consent form, and commit to attending follow-up appointments
• People aged 18 or older
• People whose general health and daily functioning is rated as fully active or restricted only in strenuous activity (confirm with trial site regarding the ECOG 0–1 rating)
• People who have been diagnosed with a specific type of esophageal cancer (squamous cell carcinoma) at a stage where the tumour has spread to nearby lymph nodes or grown into surrounding tissue, but has not spread to distant parts of the body
• People who have had surgery that completely removed the cancer (with no cancer left behind), whose recent scans show no signs of the cancer returning, and who the research team has determined need additional treatment after surgery
• People whose blood test results meet minimum thresholds for immune cell counts, red blood cell levels, liver function, kidney function, blood clotting, thyroid hormone, heart enzyme levels, and heart pumping strength (confirm specific values with trial site)

Who may not be able to join:

• People who have already received other cancer treatments after their surgery
• People who have another active cancer at the same time (except a type of skin cancer called basal cell carcinoma that has already been successfully treated)
• People whose cancer is located in the uppermost part of the oesophagus (the cervical region)
• People who have previously received certain targeted therapies or immunotherapy drugs that act on specific cancer pathways (confirm with trial site)
• People who have had a serious allergic reaction to similar types of medicines (monoclonal antibodies)
• People with a history of immune system deficiency conditions or active autoimmune disease
• People who are currently taking immune-suppressing medications, including higher-dose steroid tablets or similar hormone treatments, within two weeks of starting the trial
• People who have difficulty swallowing or absorbing oral medications
• People with fluid build-up around the lungs, heart, or abdomen that cannot be controlled and requires repeated draining
• People with a tendency to bleed, or who have had a significant bleeding event in the four weeks before starting the trial, or who have active digestive conditions that could lead to bleeding or bowel perforation
• People with active or untreated cancer spread to the brain or central nervous system
• People with high blood pressure that cannot be adequately controlled with medication (confirm thresholds with trial site)
• People with a history of heart attack, poor blood supply to the heart, certain uncontrolled heart rhythm problems, or a specific level of heart failure (confirm with trial site)
• People with an active or uncontrolled serious infection
• People who test positive for HIV
• People with significant protein detected in their urine above a confirmed threshold (confirm with trial site)
• People who have received a live or weakened vaccine within four weeks before starting the trial
• People who, in the research team's judgement, have other factors that could put them at risk or prevent them from completing the study

Important: Always verify eligibility with the trial site directly before applying.